Effects of Shexiang injection on expression of CD54 of mononuclear cells and soluble vascular cell adhesion molecule-1 in patients with acute cerebral infarction.
- Author:
Yu-sheng WU
1
;
Qian HOU
;
Dao-jie ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Cerebral Infarction; blood; drug therapy; Drug Administration Schedule; Drugs, Chinese Herbal; administration & dosage; therapeutic use; Female; Humans; Injections, Intravenous; Intercellular Adhesion Molecule-1; blood; Leukocytes, Mononuclear; drug effects; metabolism; Male; Middle Aged; Phytotherapy; Treatment Outcome; Vascular Cell Adhesion Molecule-1; blood
- From: Chinese Journal of Integrated Traditional and Western Medicine 2006;26(4):308-310
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical efficacy of Shexiang Injection (SI) on inflammatory reaction in patients with acute cerebral infarction (ACI).
METHODSForty-two patients with ACI were randomly divided into two groups, 21 in each group. The control group treated with conventional therapy and the SI group treated with conventional therapy plus SI. Besides, 21 healthy people were arranged in the normal group for control. Expression of CD54 of mononuclear cell (MC-CD54) and serum level of soluble vascular cell adhesion molecule-1 (sVCAM-1) were determined and the clinical efficacy was observed dynamically before treatment and on the 7th, 14th day of the course.
RESULTSLevels of MC-CD54 expression and sVCAM-1 in the ACI patients increased obviously (P < 0.01), reached the peak on the 7th day, and declined obviously on the 14th day in both groups, however, the lowering in the SI group was more significant than that in the control group (P < 0.01); and positive correlation was shown between these two indexes (P < 0.01). After treatment, score of neural defect was improved more significantly (P < 0.01), and the markedly effective and curative rate was higher in the SI group than those in the control group (P < 0.05), respectively.
CONCLUSIONSI could inhibit the subsequent inflammatory reaction, and thus improve the clinical efficacy of conventional therapy in treating patients with ACI.
